HC Wainwright reissued their buy rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $17.50 target price on the biopharmaceutical company’s stock. A number of other research firms also recently commented on VSTM. Royal Bank of Canada reaffirmed an outperform rating […]
Verastem (NASDAQ:VSTM – Free Report) had its target price decreased by Royal Bank of Canada from $32.00 to $16.00 in a research note released on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical company’s stock. Several other brokerages also recently commented on VSTM. HC Wainwright reiterated a […]
Verastem (NASDAQ:VSTM – Free Report) had its target price trimmed by Alliance Global Partners from $34.00 to $20.00 in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on VSTM. Royal Bank of Canada […]
Verastem (NASDAQ:VSTM – Free Report) had its price objective cut by Royal Bank of Canada from $32.00 to $16.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. Several other brokerages have also weighed in on VSTM. StockNews.com raised Verastem from a […]
Verastem (NASDAQ:VSTM – Free Report) had its target price trimmed by Royal Bank of Canada from $32.00 to $16.00 in a report published on Tuesday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. Several other equities research analysts have also recently issued reports on VSTM. HC Wainwright reiterated a buy […]